Charton M, Timbal Y
Department of Urology, Porte de Choisy Medico-Surgical Center, Paris, France.
Eur Urol. 1990;17(3):252-6. doi: 10.1159/000464050.
Enoxacin is a new quinolone derivative that is well absorbed after oral administration and shows good efficacy against the pathogenic bacteria usually isolated in urinary infections. We studied the diffusion of enoxacin in healthy renal tissue (13 patients) and adenomatous prostate tissue (16 patients) in surgical patients dosed with enoxacin preoperatively. The plasma and parenchymal concentrations were measured by high-performance liquid chromatography after 5 successive oral doses of 400 mg given at 12-hour intervals. The mean concentrations for the prostatic series were: 5.15 +/- 2.68 micrograms/g of adenomatous prostatic tissue and 2.07 +/- 1.38 mg/l of plasma 2 h after the last dose (r = 2.54); 2.5 +/- 1.7 micrograms/g and 0.98 +/- 0.8 mg/l, respectively, 15 h after the last dose (r = 2.61). The mean concentration of enoxacin in the kidney 3 h after the last dose was 13.93 micrograms/g (r = 7.35); the concentrations 12 h after the last dose ranged from 9.70 to 14.35 micrograms/g of tissue and from 1.1 to 2.3 mg/l of plasma (r = 7.76). Consequently, enoxacin appears to have interesting possibilities for the treatment of urological parenchymal infections.
依诺沙星是一种新型喹诺酮衍生物，口服后吸收良好，对尿路感染中常见的病原菌显示出良好疗效。我们研究了依诺沙星在术前接受依诺沙星给药的外科手术患者的健康肾组织（13例患者）和腺瘤性前列腺组织（16例患者）中的扩散情况。在以12小时间隔连续口服5次400 mg剂量后，通过高效液相色谱法测量血浆和实质组织浓度。前列腺组的平均浓度为：末次给药后2小时，腺瘤性前列腺组织为5.15±2.68微克/克，血浆为2.07±1.38毫克/升（r = 2.54）；末次给药后15小时，分别为2.5±1.7微克/克和0.98±0.8毫克/升（r = 2.61）。末次给药后3小时，肾脏中依诺沙星的平均浓度为13.93微克/克（r = 7.35）；末次给药后12小时，组织浓度范围为9.70至14.35微克/克，血浆浓度范围为1.1至2.3毫克/升（r = 7.76）。因此，依诺沙星在治疗泌尿外科实质感染方面似乎有有趣的应用前景。
